DOCSLIB.ORG

Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multi- Region Single-Cell Sequencing

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multi- Region Single-Cell Sequencing Resolving the spatial and cellular architecture of lung adenocarcinoma by multi- region single-cell sequencing SUPPLEMENTARY DATA FILE 2 Supplementary Figures S1-S7 Supplementary Fig. S1 Count matrix Filtering Removal of: Doublets Low quality cells Cells with low complexity libraries/debris Batch effects evaluation and correction Unsupervised clustering, UMAP visualization & major cell lineages annnotation Hierarchical relationship analysis EPCAM- fractions EPCAM+ fractions Subclustering & cell subsets annotation Sublustering & cell subsets annotation Confirmation of subclustering robustness Confirmation of subclustering robustness for specific EPCAM- subsets Stromal inferCNV analysis and clustering Differential gene expression analysis Single-cell trajectory analysis of specific subpopulations Immune Lymphoid Analysis of cell Myeloid states & signatures Cell-Cell communication analysis Supplementary Fig. S1. Schematic view of the bioinformatics analysis workflow. An overview of the quality control steps and analyses done. Supplementary Fig. S2 A 10k 0.15 6k 5k 1k 0.10 4k 3k # of cell 100 0.05 2k 1k # of detected genes fraction of mito-genes 10 0.00 0 4 2 1 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 2 1 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 2 1 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ 4 Ep- 4 Ep+ 3 Ep- 3 Ep+ 2 Ep- 2 Ep+ 1 Ep- 1 Ep+ Patient P1 P2 P3 P4 P5 P1 P2 P3 P4 P5 P1 P2 P3 P4 P5 1 2 3 4 LUAD Adj Int Dis B D EpithelialLymphoidMyeloidStromal LAMP3 Patient P1 P2 P3 n = 186,916 KRT8 P1 NKX2−1 EPCAM P2 KRT17 TP63 P3 KRT5 PTPRC P4 GZMB GZMA Scaled exp P5 MZB1 P4 P5 XCL2 CD8B 1.0 CD8A GZMK 0.5 XCL1 0.0 CD40LG SLAMF7 −0.5 TRGV8 −1.0 NCAM1 KLRC1 NCR1 CD19 % expressed TRDC MS4A1 0 LILRB4 25 ITGAX C S100A8 50 S100A9 75 Batch CD14 n = 186,916 PM1127 CD4 100 PM1178 HLA−DPB1 HLA−DRB1 PM1157_1158 CD68 SC153 FCER1G CD1C SC172 TPSB2 PM1127 PM1178 PM1157_1158 SC153 TPSAB1 SC174 MS4A2 LILRA4 PM1137 CLEC9A CLDN5 PECAM1 PDGFRA SERPINF1 ACTA2 COL1A2 SC172 SC174 PM1137 PDGFRB COL1A1 Supplementary Fig. S2. Quality control metrics and expression of major cell lineage markers across the spatial LUAD scRNA-seq dataset. A, Statistical summary of cells passing quality control (QC) and showing cell number (left), fraction of mitochondrial genes (middle), and the number of detected genes (right) per sample. Dis, distant normal; Int, intermediate normal; Adj, adjacent normal; LUAD, tumor tissue. B-C, UMAP plots showing cells colored by patient ID (B) and library/sequencing batch (C). D, Bubble plot showing the percentage of cells expressing lineage markers (indicated by the size of the circle) as well as their scaled expression levels (indicated by the color of the circle) across all cells (related to main Fig. 1D and Fig. 1E). Supplementary Fig. S3 A Harmony rPCA Cluster overlap Ratio of overlap: 98.4% rPCA Endothelial Epithelial Jaccard Stromal_C17.C14 index Stromal 8 11 3 4 5997 Myeloid_C2.C6..C22 0 177 837 34020 0 Lymphoid Myeloid Lymphoid_C1.C3...C10 12 1 39510 319 9 Endothelial Lymphoid Epithelial_C0.C4..C18 0 52325 0 19 0 1.00 Lymphoid Myeloid 0.75 Endothelial_C9.C21 6932 0 0 0 2 Epithelial 0.50 Myeloid 0.25 Epithelial Myeloid Stromal EpithelialLymphoid Endothelial 0.00 Harmony Stromal B 25% cells sampled 50% cells sampled 75% cells sampled Epithelial Epithelial Endothelial Lymphoid Stromal Endothelial Myeloid Lymphoid Lymphoid Endothelial Stromal Stromal Myeloid Epithelial Myeloid Cluster overlap Cluster overlap Cluster overlap Ratio of overlap: 99.5% Ratio of overlap: 99.8% Ratio of overlap: 99.7% Stromal_C13.C15 Stromal_C14.C16 Stromal_C14.C17 12 0 0 0 6003 1 0 0 0 1964 10 0 0 0 3937 Myeloid_C1.C6.C11.C12.C18.C20 0 0 0 10978 1 Myeloid_C10.C13.C3.C6.C20.C12 0 0 1 22020 1 Myeloid_C4.C13.C6.C10.C20.C12.C24 0 0 1 33237 1 Lymphoid_C3.C5.C7.C19.C14.C9 4 1 13202 22 2 Lymphoid_C2.C4.C7.C21.C17.C9 2 3 26573 10 1 Lymphoid_C2.C3.C7.C22.C16.C8 1 7 39536 7 1 Epithelial_C0.C2.C10.C4.C16 9 17467 0 0 18 Epithelial_C0.C1.C11.C5.C15.C18 5 34880 0 1 3 Epithelial_C0.C1.C5.C11.C15.C18.C25 4 52355 0 1 1 Endothelial_C8.C21 2410 0 0 0 2 Endothelial_C8.C22 4599 0 0 0 4 Endothelial_C9.C21.C23 6935 0 0 0 2 MyeloidStromal MyeloidStromal MyeloidStromal EpithelialLymphoid EpithelialLymphoid EpithelialLymphoid Endothelial Endothelial Endothelial Jaccard index Cell type 0 0.25 0.50 0.75 1 Cell type (100% cells) (random sampling) C Cluster overlap Ratio of overlap: 97.0% C2 1 0 0 0 782 Jaccard index C1 0 0 2 4002 0 1 0.75 C7 36 12 5666 896 12 0.50 0.25 C3.C4.C6 1 7345 0 4 0 0 C5 869 0 0 0 0 MyeloidStromal EpithelialLymphoid Endothelial Cell type Cell type (100% cells) (K-means clustering) Supplementary Fig. S3. Analysis of clustering robustness of major cellular lineages. A, UMAP plots showing cells colored by major lineages and identified with Harmony (left) or rPCA (middle). The right part of panel A shows a heatmap depicting the extent of cluster assignment overlap between rPCA (rows) and Harmony results (columns) as quantified by Jaccard index. B, UMAP plots (top) and the corresponding cluster overlap indices (bottom) when using 25% (left), 50% (middle), and 75% (right) of randomly sampled cells. The heatmaps show cluster overlap indices in randomly sampled results (rows) versus when using all 186,916 cells (columns). C, Heatmap depicting the extent of cluster assignment overlap between k-means clustering (columns) and Harmony (rows) as quantified by Jaccard index. Supplementary Fig. S4 A 1.0 1.0 P = 0.07 1.0 0.8 0.8 0.8 0.6 0.6 0.5 0.4 0.4 0.3 Fraction (Proliferating) 0.2 0.2 Fraction (Non-proliferating) Fraction (Proliferating epithelial) 0.0 0.0 0.0 LUAD Other MyeloidStromal Myeloid EpithelialLymphoid Epithelial Lymphoid Endothelial 1 2 3 4 LUAD Adj Int Dis B 50k P < 0.001 6,000 P < 0.001 40k 4,500 30k 20k 3,000 # genes (All cells) (All cells) # transcripts 10k 1,500 0 0 Ep+ Ep- Ep+ Ep- (n = 623) (n = 14,509) (n = 623) (n = 14,509) C 40k P < 0.01 6,000 P < 0.01 30k 4,500 20k 3,000 # genes 10k # transcripts 1,500 (Proliferating cells) (Proliferating cells) 0 0 Ep+ Ep- Ep+ Ep- (n = 7) (n = 139) (n = 7) (n = 139) D 40k P < 0.001 6000 P < 0.001 30k 4500 20k 3000 # genes 10k # transcripts 1500 0 (Non-proliferating cells) (Non-proliferating cells) 0 Ep+ Ep- Ep+ Ep- (n = 616) (n = 14,370) (n = 616) (n = 14,370) E Relative expression % of cells expressed 0 1 2 3 0 25 50 75 100 NK B T Mac DC EC Y L A2 IL6 T XP3 CA4 CD4 IL10 CD7 IL1B VWF PTX3 PRF1 C XCL1 CD14 CD68 XBP1 CD19 XCL2 O SDC1 MZB1 CD8A NCR1 CD3E CD8B CD3D GN CD1C TRDC IL2RA NKG7 GZMA GZMB GZMK ITGAX A F TPSB2 KLRC1 KLRB1 MS4A1 TRGV8 TRGC1 MS4A2 CLDN5 TRGC2 PTPRC LILRB4 LILRA4 NCAM1 S100A8 S100A9 COL1A1 TPSAB1 CD40LG CLEC9A COL1A2 FCER1G FCGR3A SLAMF7 PECAM1 PDGFRA PDGFRB SERPINF1 HLA−DPB1 HLA−DRB1 Supplementary Fig. S4. Analysis of expression markers among epithelial and immune cell fractions. A, Stacked bar plots showing the relative cell fraction of spatial samples for major lineages considering non-proliferating cells (left) and proliferating ones (middle). Box plot showing fraction of proliferating epithelial cells in LUAD tissues versus normal spatial samples (right). P – value was calculated using Wilcoxon rank sum test. B, Boxplots showing the number of detected transcripts (left) and the number of detected genes (right) in epithelial cells versus in all non-epithelial lineages including lymphoid, myeloid, and stromal cells. C, Boxplots showing the number of detected transcripts (left) and the number of detected genes (right) in proliferating epithelial cells versus in proliferating cells of non-epithelial lineages including lymphoid, myeloid, and stromal cells. D, Boxplots showing the number of detected transcripts (left) and genes (right) in non-proliferating epithelial cells versus in non-proliferating and non-epithelial lineages including lymphoid, myeloid, and stromal cells. E, Bubble plot showing the percentage of cells expressing lineage markers (indicated by the size of the circle) as well as their scaled expression levels (indicated by the color of the circle) across selected cell types (related to main Fig. 1G and Fig. 1H). NK; natural killer cell, DC; dendritic cell, EC; endothelial cell. Supplementary Fig. S5 A B P1 P2 P3 PM1127 PM1178 PM1157_PM1158 n=14,279 n=5,118 n=24,541 SC153 SC172 SC174 P4 P5 n=623 n=18,761 n=6,708 C 25% cells sampled 50% cells sampled 75% cells sampled Ionocyte Ionocyte Ionocyte Proliferating Basal basal Malignant Malignant Malignant Basal enriched Proliferating enriched enriched basal Basal Ciliated Club and Proliferating Club and secretory basal secretory Club and AT2 secretory AT2 Bronchio- Bronchio- AT2 alveolar Ciliated alveolar Alveolar Alveolar Ciliated progenitor AT1 AT1 Alveolar progenitor Bronchio- progenitor AT1 alveolar Cluster overlap Cluster overlap Cluster overlap Ratio of overlap: 93.3% Ratio of overlap: 95.8% Ratio of overlap: 97.6% C2_2.Ionocyte 0 0 0 0 0 0 0 0 0 18 C9.Ionocyte 0 0 0 0 0 0 0 0 0 32 C9.Ionocyte 0 0 0 0 0 0 0 0 0 45 C7.Proliferating.basal 0 0 0 0 0 2 0 0 96 0 C8.Proliferating.basal 0 0 0 0 0 0 3 0 209 0 C8.Proliferating.basal 1 0 3 0 0 3 2 0 326 0 C6.Ciliated 0 0 0 0 0 0 0 763 0 0 C6.Ciliated 0 0 0 0 0 0 0 1612 0 0 C6.Ciliated 0 0 0
Load more

Recommended publications
  • Anti-NCR1 Antibody [29A1.4] (FITC) (ARG23568)
    Product datasheet [email protected] ARG23568 Package: 50 μg anti-NCR1 antibody [29A1.4] (FITC) Store at: 4°C Summary Product Description FITC-conjugated Rat Monoclonal antibody [29A1.4] recognizes NCR1. Rat anti Mouse CD335 antibody, clone 29A1.4 recognizes natural killer cell p46-related protein (NKp46), otherwise known as CD335, which is uniquely expressed by resting and activated natural killer (NK) cells, but no expression of CD335 has been detected on B cells, T cells, monocytes or granulocytes. It is a major NK cell lysis receptor for autologous pathogen-infected and tumor target cells during natural cytotoxicity responses. Ligands of CD335 include viral hemagglutinins (HAs) and heparan sulfate proteoglycans (HSPGs) on the surface of tumor cells. Staining with Rat anti mouse CD335 (29A1.4) is not strain specific and the antibody has been used to stain C57BL/6, SJL, CBA/CA and BALB/c strains. Clone 29A1.4 also activates NK cells in vitro. It does not deplete NK cells in vivo. Tested Reactivity Ms Tested Application FACS Host Rat Clonality Monoclonal Clone 29A1.4 Isotype IgG2a Target Name NCR1 Antigen Species Mouse Immunogen NKP46-IgG1 Fc fusion protein. Conjugation FITC Alternate Names CD antigen CD335; Natural killer cell p46-related protein; Lymphocyte antigen 94 homolog; Natural cytotoxicity triggering receptor 1; hNKp46; NKP46; NKp46; NK cell-activating receptor; LY94; CD335; NK- p46 Application Instructions Application table Application Dilution FACS 1:2 - 1:5 Application Note FACS: Use 10 µl of the suggested working dilution to label 10^6 cells in 100 µl. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist.
    [Show full text]
  • Receptor Nkp46 Cells by the NK Β Murine Pancreatic Recognition And
    Recognition and Killing of Human and Murine Pancreatic β Cells by the NK Receptor NKp46 This information is current as Chamutal Gur, Jonatan Enk, Sameer A. Kassem, Yaron of September 27, 2021. Suissa, Judith Magenheim, Miri Stolovich-Rain, Tomer Nir, Hagit Achdout, Benjamin Glaser, James Shapiro, Yaakov Naparstek, Angel Porgador, Yuval Dor and Ofer Mandelboim J Immunol 2011; 187:3096-3103; Prepublished online 17 Downloaded from August 2011; doi: 10.4049/jimmunol.1101269 http://www.jimmunol.org/content/187/6/3096 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2011/08/18/jimmunol.110126 Material 9.DC1 References This article cites 29 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/187/6/3096.full#ref-list-1 Why The JI? Submit online. by guest on September 27, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Recognition and Killing of Human and Murine Pancreatic b Cells by the NK Receptor NKp46 Chamutal Gur,*,†,1 Jonatan Enk,*,1 Sameer A.
    [Show full text]
  • Stroma-Free, Serum-Free Expansion and Differentiation of Hematopoietic Stem and Progenitor Cells to the T Cell Lineage Nooshin Tabatabaei-Zavareh1, Tim A
    Stroma-free, serum-free expansion and differentiation of hematopoietic stem and progenitor cells to the T cell lineage Nooshin Tabatabaei-Zavareh1, Tim A. Le Fevre1, Alexander J.Y. Man1, Evan A. Karas1, Stephen J. Szilvassy1, Terry E. Thomas1 , Allen C. Eaves1,2, and Albertus W. Wognum1 1 STEMCELL Technologies Inc., Vancouver, BC, Canada 2 Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada Introduction The use of T cells for cancer immunotherapy and other therapeutic applications relies on the isolation of T cells from peripheral blood and their subsequent activation and expansion in culture. T cells can also be generated from hematopoietic stem and/or progenitor cells (HSPCs) in cord blood (CB) or bone marrow (BM). This approach not only offers a renewable source of T cells, but also provides a model system to study disease mechanisms or validate new drugs that affect T cell development and/or function. Differentiation of HSPCs to T cells typically requires co-culture with stromal cell lines that have been engineered to express a Notch-ligand. In such cultures, CD34+CD38-/lo HSPCs develop into CD7+CD5+ pro-T cells that further differentiate to T lineage-committed progenitor cells (pre-T cells) characterized by the expression of CD1a. CD7+CD1a+ pre-T cells can then differentiate to express CD4 and become CD4 immature single-positive (CD4ISP) cells. CD4ISP cells give rise to CD4+CD8+ double positive (DP) cells. These finally mature into CD4 and CD8 single-positive (SP) CD3+TCRαβ+ T cells. Here we describe a serum-free culture method that recapitulates these differentiation steps in the absence of stromal cells and generates large numbers of functional T lineage cells from a limited number of purified CD34+ CB cells.
    [Show full text]
  • Receptor Nkp46/NCR1 Tumors in the Absence of the NK-Activating
    The Journal of Immunology Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR11 Gili G. Halfteck, Moran Elboim, Chamutal Gur, Hagit Achdout, Hormas Ghadially, and Ofer Mandelboim2 The in vitro elimination of virus-infected and tumor cells by NK cells is regulated by a balance between signals conveyed via specific inhibitory and activating receptors. Whether NK cells and specifically the NK-activating receptor NKp46 (NCR1 in mice) are directly involved in tumor eradication in vivo is still largely unknown. Since the NKp46/NCR1 tumor ligands have not been identified yet, we use a screening technique to identify functional ligands for NKp46/NCR1 which is based on a cell reporter assay and discover a NCR1 ligand in the PD1.6 lymphoma line. To study whether NKp46/NCR1 is important for the eradication of PD1.6 lymphoma in vivo, we used the Ncr1 knockout Ncr1gfp/gfp mice generated by our group. Strikingly, all Ncr1 knockout mice developed growing PD1.6 tumors, whereas initial tumor growth was observed in the wild-type mice and tumors were completely rejected as time progressed. The growth of other lymphoma cell lines such as B10 and EL4 was equivalent between the Ncr1 knockout and wild-type mice. Finally, we show that PD1.6 lymphoma cells are less killed both in vitro and in vivo in the absence of NKp46/NCR1. Our results therefore reveal a crucial role for NKp46/NCR1 in the in vivo eradication of some lymphoma cells. The Journal of Immunology, 2009, 182: 2221–2230. t was hypothesized that the immune system surveys the body reduced resistance to transplanted tumor cell lines (20–22).
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Expression and Function of Nkp46 W32R
    www.nature.com/scientificreports OPEN Expression and function of NKp46 W32R: the human homologous protein of mouse NKp46 W32R Received: 14 October 2016 Accepted: 12 December 2016 (Noé) Published: 30 January 2017 Ariella Glasner, Batya Isaacson & Ofer Mandelboim Natural killer (NK) cells eradicate infected cells and tumors following the triggering of activating receptors, like the Natural Cytotoxicity Receptors (NCRs), which include NKp30, NKp44 and NKp46. NKp46 is the only NCR expressed in mice (mNKp46), and except for some Innate Lymphoid Cell (ILC) populations (ILC1/3 subsets), its expression is restricted to NK cells. Previously, a mouse named Noé was generated in which a random point mutation (W32R) impaired the cell surface expression of mNKp46. Interestingly, the Noé mice NK cells expressed twice as much of the transcription factor Helios, and displayed general non-NKp46 specific hyperactivity. We recently showed that the mNKp46 W32R (Noé) protein was expressed on the surface of various cells; albeit slowly and unstably, that it is aberrantly glycosylated and accumulates in the ER. Interestingly, the Tryptophan (Trp) residue in position 32 is conserved between humans and mice. Therefore, we studied here the human orthologue protein of mNKp46 W32R, the human NKp46 W32R. We demonstrated that NKp46 W32R is aberrantly glycosylated, accumulates in the ER, and is unstable on the cell surface. Furthermore, we showed that overexpression of NKp46 W32R or Helios resulted in augmented NK cell activation, which may be applied to boost NK activity for therapeutic applications. NK cells are innate lymphocytes, lately characterized as group I innate lymphoid cells (ILCs). They specialize in the eradication of various pathogens and cancers1–12.
    [Show full text]
  • Multiparameter Phenotype Mapping of Normal and Post-Chemotherapy B
    Leukemia (1997) 11, 1266–1273 1997 Stockton Press All rights reserved 0887-6924/97 $12.00 Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow MN Dworzak, G Fritsch, C Fleischer, D Printz, G Fro¨schl, P Buchinger, G Mann and H Gadner Children’s Cancer Research Institute, St Anna Kinderspital, Kinderspitalgasse 6, A-1090 Vienna, Austria We studied the differentiation profiles of B cell precursors Materials and methods (BCP) in normal and post-chemotherapy pediatric bone marrow (BM) using multiparameter flow cytometry. The goal of our study was to draw a comprehensive phenotypic map of the Sample description three major maturational BCP stages in BM. By correlating lin- eage-associated markers, CD45RA, and several adhesion mol- Pediatric bone marrow (BM) samples (n = 44) were obtained ecules, the stage-specific patterns were found to differ in cer- from children undergoing diagnostic BM aspiration for the fol- tain details from previously published concepts. Among the earliest BCP, a subset of CD34+CD10lo precursors was repeat- lowing diagnoses in the absence of BM involvement at the edly observed in addition to the well characterized time of immunologic investigation: suspicion of storage dis- CD34+CD10hiCD19+ majority of cells. Only two-thirds of these ease (n = 1), bacterial lymphadenitis (n = 1), neuroblastoma CD34+CD10lo cells expressed CD19. However, uniformity of (n = 1), severe aplastic anemia in remission (n = 2), single sys- phenotypic features, absence of T lineage markers, and the tem Langerhans cell histiocytosis (n = 1), idiopathic throm- regeneration kinetics after chemotherapy suggest the B lineage = + lo bocytopenic purpura (n 1), early stage (localized) non- affiliation of the CD34 CD10 precursors in general.
    [Show full text]
  • Targeting HIF-1 Alpha Transcriptional Activity Drives Cytotoxic Immune Effector Cells Into Melanoma and Improves Combination Immunotherapy
    Oncogene (2021) 40:4725–4735 https://doi.org/10.1038/s41388-021-01846-x BRIEF COMMUNICATION Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy 1 1 1 1 1 Audrey Lequeux ● Muhammad Zaeem Noman ● Malina Xiao ● Kris Van Moer ● Meriem Hasmim ● 1 1 1 1 1,2 3,4 Alice Benoit ● Manon Bosseler ● Elodie Viry ● Tsolere Arakelian ● Guy Berchem ● Salem Chouaib ● Bassam Janji 1 Received: 31 August 2020 / Revised: 27 April 2021 / Accepted: 17 May 2021 / Published online: 21 June 2021 © The Author(s) 2021. This article is published with open access Abstract Hypoxia is a key factor responsible for the failure of therapeutic response in most solid tumors and promotes the acquisition of tumor resistance to various antitumor immune effectors. Reshaping the hypoxic immune suppressive tumor microenvironment to improve cancer immunotherapy is still a relevant challenge. We investigated the impact of inhibiting HIF-1α transcriptional activity on cytotoxic immune cell infiltration into B16-F10 melanoma. We showed that tumors 1234567890();,: 1234567890();,: expressing a deleted form of HIF-1α displayed increased levels of NK and CD8+ effector T cells in the tumor microenvironment, which was associated with high levels of CCL2 and CCL5 chemokines. We showed that combining acriflavine, reported as a pharmacological agent preventing HIF-1α/HIF-1β dimerization, dramatically improved the benefit of cancer immunotherapy based on TRP-2 peptide vaccination and anti-PD-1 blocking antibody. In melanoma patients, we revealed that tumors exhibiting high CCL5 are less hypoxic, and displayed high NK, CD3+, CD4+ and CD8+ T cell markers than those having low CCL5.
    [Show full text]
  • Arming Tumor-Associated Macrophages to Reverse Epithelial
    Published OnlineFirst August 15, 2019; DOI: 10.1158/0008-5472.CAN-19-1246 Cancer Tumor Biology and Immunology Research Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression Hiromi I.Wettersten1,2,3, Sara M.Weis1,2,3, Paulina Pathria1,2,Tami Von Schalscha1,2,3, Toshiyuki Minami1,2,3, Judith A. Varner1,2, and David A. Cheresh1,2,3 Abstract Tumor-associated macrophages (TAM) are highly expressed it engaged macrophages but not natural killer (NK) cells to within the tumor microenvironment of a wide range of cancers, induce antibody-dependent cellular cytotoxicity (ADCC) of where they exert a protumor phenotype by promoting tumor avb3-expressing tumor cells despite their expression of the cell growth and suppressing antitumor immune function. CD47 "don't eat me" signal. In contrast to strategies designed Here, we show that TAM accumulation in human and mouse to eliminate TAMs, these findings suggest that anti-avb3 tumors correlates with tumor cell expression of integrin avb3, represents a promising immunotherapeutic approach to redi- a known driver of epithelial cancer progression and drug rect TAMs to serve as tumor killers for late-stage or drug- resistance. A monoclonal antibody targeting avb3 (LM609) resistant cancers. exploited the coenrichment of avb3 and TAMs to not only eradicate highly aggressive drug-resistant human lung and Significance: Therapeutic antibodies are commonly engi- pancreas cancers in mice, but also to prevent the emergence neered to optimize engagement of NK cells as effectors. In of circulating tumor cells. Importantly, this antitumor activity contrast, LM609 targets avb3 to suppress tumor progression in mice was eliminated following macrophage depletion.
    [Show full text]
  • Tumor-Responsive, Multifunctional CAR-NK Cells Cooperate with Impaired Autophagy to Infiltrate and Target Glioblastoma
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.07.330043; this version posted October 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Tumor-responsive, multifunctional CAR-NK cells cooperate with impaired autophagy to infiltrate and target glioblastoma Jiao Wang1, Sandra Toregrosa-Allen2, Bennett D. Elzey2, Sagar Utturkar2, Nadia Atallah Lanman2,3, Victor Bernal-Crespo4, Matthew M. Behymer1, Gregory T. Knipp1, Yeonhee Yun5, Michael C. Veronesi5, Anthony L. Sinn6, Karen E. Pollok6,7,8,9, Randy R. Brutkiewicz10, Kathryn S. Nevel11, Sandro Matosevic1,2* 1Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN, USA 2Center for Cancer Research, Purdue University, West Lafayette, IN, USA 3Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA 4Histology Research Laboratory, Center for Comparative Translational Research, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA. 5Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA 6In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA 7Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA 8Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of
    [Show full text]
  • Ncounter Fibrosis Panel
    PRODUCT BULLETIN nCounter® Fibrosis Panel Gene Expression Panel Four Stages of Fibrosis • Disease Pathogenesis • Biomarkers of Progression Uncover the mechanisms of disease pathogenesis, identify biomarkers of progression, and develop signatures for therapeutic response with the nCounter Fibrosis Panel. This gene expression panel combines hundreds of genes involved in the initial tissue damage response, chronic inflammation, proliferation of pro-fibrotic cells, and tissue modification that leads to fibrotic disease of the lungs, heart, liver, kidney, and skin. INITIATION Product Highlights • Profile 770 genes across 51 annotated pathways involved in the four stages of fibrosis T is s s • Initiation s u e e r I • t D N Inflammation N S a F l m • Proliferation O l L I e a A g • Modification T C M e A M C • I Study pathogenesis and identify biomarkers for fibrotic A F I T diseases of the lungs, heart, liver, kidney, and skin I D O O N • Understand the signaling cascade from cell M stress to inflammation • Quantify the relative abundance of 14 different W g ound Healin immune cell types • Identify biomarkers of therapeutic response PR N OLIFERATIO Feature Specifications Number of Targets 770 (Human), 770 (Mouse), including internal reference genes Standard Input Material (No amplification required) 25-300 ng Sample Input - Low Input As little as 1 ng with nCounter Low Input Kit (sold separately) Cultured cells/cell lysates, sorted cells, FFPE-derived RNA, total RNA, Sample Type(s) fragmented RNA, PBMCs, and whole blood/plasma Add up to 55 unique genes with Panel-Plus and up to 10 custom Customizable protein targets Time to Results Approximately 24 hours Data Analysis nSolver™ Analysis Software (RUO) FOR RESEARCH USE ONLY.
    [Show full text]
  • IL-27R Signaling Serves As Immunological Checkpoint for NK Cells to Promote Hepatocellular Carcinoma
    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.28.424635; this version posted December 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. IL-27R signaling serves as immunological checkpoint for NK cells to promote hepatocellular carcinoma Turan Aghayev1, Iuliia O. Peshkova1, Aleksandra M. Mazitova1, 3, Elizaveta K. Titerina1, Aliia R. Fatkhullina1, Kerry S. Campbell1, Sergei I. Grivennikov2, 4, Ekaterina K. Koltsova1, 4, 5 1Blood Cell Development and Function Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA 2 Cancer Prevention and Control Program, Fox Chase Cancer Center, Philadelphia, PA, 19111, USA 3Kazan Federal University, Kazan, 42008, Russia 4Cedars Sinai Medical Center, Department of Medicine, 8700 Beverly Blvd, Los Angeles, CA, 900048 5Corresponding and Lead Author, contact: Ekaterina Koltsova, MD, PhD, Department of Medicine, Cedars Sinai Medical Center, Department of Medicine, 8700 Beverly Blvd, Los Angeles, CA, 900048, USA. E-mail: [email protected] Running title: IL-27R signaling suppress anti-cancer NK cells in HCC The authors declare no potential conflicts of interest. 1 bioRxiv preprint doi: https://doi.org/10.1101/2020.12.28.424635; this version posted December 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Hepatocellular carcinoma (HCC) is the most common form of liver cancer with poor survival and limited therapeutic options. HCC has different etiologies, typically associated with viral or carcinogenic insults or fatty liver disease and underlying chronic inflammation presents as a major unifying mechanism for tumor promotion.
    [Show full text]